오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 3.75 mg - tablet, modified release - excipient ingredients: silicon dioxide; hypromellose; magnesium stearate; calcium hydrogen phosphate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.75 mg - tablet, modified release - excipient ingredients: hypromellose; silicon dioxide; magnesium stearate; calcium hydrogen phosphate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - adenosine, quantity: 6 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - therapeutic indications: adenosine viatris is indicated for the rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (wolff-parkinson-white syndrome). diagnostic indications: adenosine viatris is indicated as an aid to diagnosis of broad or narrow qrs complex supraventricular tachycardias. although adenosine viatris is not effective in converting atrial flutter, atrial fibrillation or ventricular tachycardia to sinus rhythm, the slowing of av conduction helps diagnosis of atrial activity. in this respect adenosine should be used as an adjunct to, but not a replacement for, clinical and ecg observations. it should be used only when, despite all diagnostic attempts, doubt still persists. adenosine viatris can also be used for improved diagnostic sensitivity of intracavity electrophysiological investigations.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - triamcinolone acetonide, quantity: 40 mg/ml - injection, suspension - excipient ingredients: benzyl alcohol; sodium chloride; polysorbate 80; carmellose sodium; water for injections; sodium hydroxide; hydrochloric acid - intramuscular: the intramuscular administration of kenacort-a 40 (sterile triamcinolone acetonide suspension usp) is indicated for systemic corticosteroid therapy in such conditions as allergic diseases, dermatoses, or generalised rheumatoid arthritis and other connective tissue disorders. intramuscular administration is particularly valuable in such conditions where oral corticosteroid therapy is not feasible. intra-articular: kenacort-a 40 injection is indicated for intra-articular or intrasynovial administration and for injections into tendon sheaths as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: synovitis of osteoarthritis; rheumatoid arthritis; acute and subacute bursitis; acute gouty arthritis; epicondylitis; acute non-specific tenosynovitis; post-traumatic osteoarthritis.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - adenosine, quantity: 10 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - intravenous adenosine juno is a coronary vasodilator for use in conjunction with radionuclide myocardial perfusion imaging, in patients unable to exercise adequately.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - remifentanil hydrochloride, quantity: 5.5 iu/mg (equivalent: remifentanil, qty 5 mg) - injection, powder for - excipient ingredients: glycine; nitrogen; hydrochloric acid - -as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery in adults.,-as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical but not cardiac procedures in children aged 1 to 12 years.,-for continuation as an analgesic into the immediate post-operative period under the close supervision of medically qualified persons trained in the use of anaesthetic drugs, during transition to longer acting analgesia following adult cardiac surgery -,when endotracheal intubation and controlled ventilation are anticipated.,-for provision of analgesia and sedation in mechanically ventilated intensive care patients.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - metoprolol tartrate -

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - metoprolol tartrate -

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - nedocromil sodium -

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 0.0725 mg; fluticasone propionate, quantity: 0.25 mg - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include ? patients on effective maintenance doses of long acting beta 2 agonists and inhaled corticosteroids ? patients who are symptomatic on current inhaled corticosteroid therapy for the symptomatic treatment of patients with severe copd (fev1 not more than 50 per cent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta 2 agonist bronchodilator therapy. fluticasone salmeterol multi haler 250/50 is not indicated for the initiation of bronchodilator therapy in copd